IKT (Inhibikase Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IKT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | DENNIS N BERMAN | Director | M | — | — |
| 2026-07-31 | Rajeev M. Shah | 10%+ Owner | J | — | — |
| 2026-02-24 | Christopher Cabell | President & Head of R&D | D | — | — |
| 2026-02-24 | Amit Munshi | Director | D | — | — |
| 2026-02-24 | Vincent Aurentz | Director | D | — | — |
| 2026-01-07 | Christopher Cabell | President & Head of R&D | A | — | — |
| 2026-01-07 | David McIntyre | Chief Financial Officer | A | — | — |
| 2026-01-07 | Mark T Iwicki | Chief Executive Officer | A | — | — |
| 2025-11-24 | Sands Capital Alternatives, LLC | 10%+ Owner | Buy | — | — |
| 2025-08-28 | Amit Munshi | Director | A | — | — |
| 2025-07-02 | David Canner | Director | A | — | — |
| 2025-07-02 | DENNIS N BERMAN | Director | A | — | — |
| 2025-07-02 | Arvind Kush | Director | A | — | — |
| 2025-07-02 | Vincent Aurentz | Director | A | — | — |
| 2025-07-02 | Amit Munshi | Director | A | — | — |
| 2025-07-02 | Roberto Bellini | Director | A | — | — |
| 2025-07-02 | Christopher Cabell | President & Head of R&D | A | — | — |
| 2025-07-02 | Vincent Aurentz | Director | A | — | — |
| 2025-07-02 | Mark T Iwicki | Chief Executive Officer | A | — | — |
| 2025-04-16 | David McIntyre | Chief Financial Officer | A | — | — |
| 2025-02-25 | Mark T Iwicki | Chief Executive Officer | A | — | — |
| 2025-02-25 | Christopher Cabell | President & Head of R&D | A | — | — |
| 2025-02-25 | Vincent Aurentz | Director | A | — | — |
| 2025-02-19 | Arvind Kush | Director | A | — | — |
| 2025-02-19 | Roy Lester Freeman | Director | A | — | — |
| 2025-02-19 | Mark T Iwicki | Chief Executive Officer | A | — | — |
| 2025-02-19 | DENNIS N BERMAN | Director | A | — | — |
| 2025-02-19 | David Canner | Director | A | — | — |
| 2025-02-19 | DENNIS N BERMAN | Director | A | — | — |
| 2025-02-19 | Roberto Bellini | Director | A | — | — |
| 2025-02-19 | Amit Munshi | Director | A | — | — |
| 2025-01-22 | Garth Lees-Rolfe | Chief Financial Officer | MIXED | — | — |
| 2025-01-22 | Milton H. Werner | President and CEO | MIXED | — | — |
| 2025-01-22 | Roy Lester Freeman | Director | MIXED | — | — |
| 2025-01-22 | DENNIS N BERMAN | Director | MIXED | — | — |
| 2025-01-07 | Roy Lester Freeman | Director | A | — | — |
| 2025-01-07 | DENNIS N BERMAN | Director | A | — | — |
| 2025-01-07 | Garth Lees-Rolfe | Chief Financial Officer | A | — | — |
| 2025-01-07 | Milton H. Werner | President and CEO | A | — | — |
| 2024-10-23 | David Canner | Director | A | — | — |
| 2024-10-23 | Amit Munshi | Director | Buy | — | — |
| 2024-10-23 | Arvind Kush | Director | Buy | — | — |
| 2024-10-23 | Roberto Bellini | Director | Buy | — | — |
| 2024-07-18 | DENNIS N BERMAN | Director | A | — | — |
| 2024-07-18 | Roy Lester Freeman | Director | A | — | — |
| 2024-07-18 | Gisele Dion | Director | A | — | — |
| 2024-07-18 | PAUL C GRINT | Director | A | — | — |
| 2024-04-03 | Milton H. Werner | President and CEO | A | — | — |
| 2024-04-02 | Garth Lees-Rolfe | Chief Financial Officer | A | — | — |
| 2023-07-05 | DENNIS N BERMAN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 13,018,965 | — |
| — | 10%+ Owner | 6,970,000 | — |
| — | Director | 1,460,000 | — |
| — | President and CEO | 893,171 | — |
| — | President & Head of R&D | 676,564 | — |
| — | Director | 510,596 | — |
| — | Director | 403,176 | — |
| — | Director | 145,000 | — |
| — | Director | 21,854 | — |
| — | Cheif Financial Officer | 15,372 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IKT quote page; the site-wide leaderboard is on the insider transactions hub.